Biotech
By the Numbers: CRISPR Patent Filings Are Still Climbing a Decade In
Gene-editing patents are supposed to be a mature field by now. The PatentBear filing counts say the curve is still bending upward.
Latest Articles
12 articles indexedBiotech
The Docket: A Busy Week of Biotech Patent Grants Across Metabolic, Gene-Editing, and Eye Disease
Early June brought a cluster of issued grants spanning three of the sector's hottest franchises. Read together, they map where the money is.
By the Numbers
Biotech
Company Primer: What Regeneron's Patent Estate Reveals About the Eylea Fight
Regeneron's eye-disease franchise faces biosimilar pressure. Its recent patents show the franchise defending on a second front: the delivery device.
Biotech
Modality Explained: mRNA and the Lipid Nanoparticle That Delivers It
An mRNA drug is a set of instructions wrapped in a fat bubble. Moderna's foundational patents and a fresh 2026 lipid grant show both halves.
Biotech
What Is RNA Interference? The Quieter Cousin of mRNA Medicine, Explained
If mRNA tells your cells to make a protein, RNAi does the opposite — it tells them to stop. A 2026 coronavirus iRNA filing shows the idea in action.
Biotech
Cliff Watch: Vertex's Cystic Fibrosis Moat Has a New Name in the Patent Record
Vertex's CF franchise funds everything else it does. A June 2026 grant from a rival shows the competition is now filing its own CFTR chemistry.
Biotech
Modality Explained: Antibodies, Biosimilars, and Why Eye-Disease Patents Get Crowded
A therapeutic antibody is a precision-guided protein. A biosimilar is a near-copy. The anti-VEGF patent record shows why 'near' is the whole fight.
Biotech
Crosswalk: The Vertex and Broad Patents That Explain Casgevy's Gene-Editing Economics
Vertex's approved sickle-cell therapy edits a patient's own stem cells. Two 2026 grants — one Vertex, one Broad — show who owns which piece.
Biotech
What's the Difference Between a Patent Grant and a Patent Application?
Biotech headlines conflate the two constantly. The distinction decides whether a company can actually stop a competitor — or is just hoping to.
Biotech
CRISPR, Explained: What the Foundational Broad Institute Patent Actually Claims
Gene editing gets described as 'molecular scissors.' A 2026 Broad Institute grant shows the real machinery — and why the analogy only goes so far.
Biotech
Reality Check: The GLP-1 Patent Story Is Crowded — and the Filings Show It
The bull case treats metabolic-drug IP as an unbreachable moat. The patent record shows a field thick with competitors filing the same ideas.
Biotech
GLP-1, Explained: How Tirzepatide Actually Works — and What Lilly Patented to Protect It
The drug behind the weight-loss boom is a peptide that imitates two gut hormones at once. A 2026 Eli Lilly grant shows how the company protects it.